| ATCC 35319| Clostridium cellulolyticum| Clostridium cellulolyticum Petitdemange et al. 1984| Clostridium cellulosilyticum| DSM 5812| Ruminiclostridium cellulolyticum| strain H10
Indirect effects on human health: Ruminiclostridium cellulolyticum is not typically associated with causing diseases or infections in humans. Instead, its primary ecological niche is within the digestive tracts of ruminant animals, where it contributes to the fermentation of plant material and the production of metabolites that can benefit the host animal. While Ruminiclostridium cellulolyticum itself may not directly impact human health, its activities within the digestive systems of animals can indirectly affect human health through the production of food products such as meat and dairy.
Potential for biotechnological applications: The cellulolytic capabilities of Ruminiclostridium cellulolyticum have attracted interest for potential biotechnological applications, particularly in the context of biofuel production and biomass conversion. The bacterium's ability to efficiently degrade cellulose and other plant polysaccharides could be harnessed for the production of renewable biofuels and other valuable bioproducts. Research into the enzymatic pathways and metabolic processes of Ruminiclostridium cellulolyticum may yield insights into its biotechnological potential and applications.
Ecological significance: Ruminiclostridium cellulolyticum plays a significant role in the ecology of ruminant digestive systems and terrestrial ecosystems. As a cellulolytic bacterium, it contributes to the breakdown of plant material and the recycling of organic matter in environments such as grasslands, forests, and agricultural ecosystems. Understanding the ecological interactions and metabolic activities of Ruminiclostridium cellulolyticum in natural and managed ecosystems is important for ecosystem health and functioning.
A lot more information is available when you are logged in and raise the display level
Other Sources for more information:
Statistics | NCBI | Data Punk | End Products Produced |
Different labs use different software to read the sample. See this post for more details.
One lab may say you have none, another may say you have a lot! - This may be solely due to the software they are using to estimate.
We deem lab specific values using values from the KM method for each specific lab to be the most reliable.
Lab | Frequency | UD-Low | UD-High | KM Low | KM High | Lab Low | Lab High | Mean | Median | Standard Deviation | Box Plot Low | Box Plot High | KM Percentile Low | KM Percentile High |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other Labs | 0.4 | 10 | 323 | 0 | 294 | 95 | 70 | 101.5 | 10 | 323 | 9.1 %ile | 81.8 %ile | ||
biomesight | 34.53 | 0 | 20 | 10 | 1480 | 0 | 1427 | 226.2 | 50 | 612.7 | 0 | 270 | 2.5 %ile | 97.3 %ile |
thorne | 96.55 | 1 | 29 | 0 | 28 | 14.1 | 14 | 7.3 | 4 | 22 | 0 %ile | 100 %ile | ||
thryve | 0.09 | 0 | 110 | 110 | 110 | 110 | 110 | 0 %ile | 99 %ile |
Source of Ranges | Low Boundary | High Boundary | Low Boundary %age | High Boundary %age |
---|---|---|---|---|
Thorne (20/80%ile) | 4.43 | 12.11 | 0.0004 | 0.0012 |
Lab | Frequency Seen | Average | Standard Deviation | Sample Count | Lab Samples |
---|---|---|---|---|---|
Biomesight | 36.662 % | 0.021 % | 0.058 % | 1050.0 | 2864 |
bugspeak | 100 % | 0.007 % | % | 1.0 | 1 |
CerbaLab | 66.667 % | 0.003 % | 0.001 % | 2.0 | 3 |
custom | 3.39 % | 0.017 % | 0.022 % | 2.0 | 59 |
es-xenogene | 13.793 % | 0.01 % | 0.007 % | 4.0 | 29 |
Thorne | 76.136 % | 0.001 % | 0.001 % | 67.0 | 88 |
Thryve | 0.145 % | 0.146 % | 0.192 % | 2.0 | 1383 |
Click on Impact for information if high or low levels are causing the impact
Magnitude | Impact | Symptom |
---|
|
And display level must be raised above public.
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.